Michael Parini News Today

Freeline Therapeutics is at the forefront of developing groundbreaking gene therapies for chronic diseases.

Freeline Reports Second Quarter 2023 Financial Results and Business Highlights Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect...

BioPharma

Shares of Freeline Therapeutics Holdings plc (FRLN) are gaining over 10% on Wednesday morning after the company reported positive initial clinical data from first cohort of phase 1/2 trial of FLT201, its novel gene therapy candidate in Gaucher disease.

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Q2 2023 Earnings Call Transcript August 15, 2023 Freeline Therapeutics Holdings plc misses on earnings expectations. Reported EPS is $-4.16 EPS, expectations were $3.62. Operator: Good morning, everyone, and welcome to the Freeline Second Quarter 2023 Financial and Business Update Conference Call. All participants will be in a listen-only mode. […]

31.07.2023 - LONDON, July 31, 2023 (GLOBE NEWSWIRE) - Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company will be participating in two upcoming investor conferences in August. Details are as follows: BTIG Virtual Biotechnology ...

Syncona Ltd - London-based investor in healthcare companies - Reports first-quarter results of investee Freeline Therapeutics Holdings PLC. Freeline is a clinical-stage biotechnology company.... | May 30, 2023

IN BRIEF: Syncona investee Freeline swings to first-quarter profit | Financial News

Operator: Good day, everyone. Welcome to the Freeline Therapeutics Business Update Conference Call. At this time, all participants are in listen-only mode.

In an effort to improve its cash runway, the UK biotech company Freeline Therapeutics has paused the development of a gene therapy candidate for the rare metabolic condition Fabry disease. Instead, the company will refocus its efforts on a gene therapy for a different metabolic condition called Gaucher disease.